Biontech Se

Tron—translationale Onkologie an Der Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Ggmbh

Biontech Rna Pharmaceuticals Gbmh

Tron-Translationale Onkologie an Der Universitätsmedzin Der Johannes Gutenberg-Universität Mainz Ggmbh

Tron—translationale Onkologie an Der Universitátsmedizin Der Johannes Gutenberg—universität Mainz Gemeinnützige Gmbh

Biontech Rna Pharmaceuticals Gmbh

Sebastian Boegel

Ugur Sahin

Martin Löwer

Barbara Schrörs

Arbel David Tadmor

Mathias Vormehr

Martin Lower

Sebastian Kreiter

John Christopher Castle

Arbel D Tadmor

Barbara Schrors

Martin LÖWER

The present invention relates to methods for predicting peptides or polypeptides such as T cell epitopes useful for immunotherapy such as for vaccination. In particular, the present invention relates to methods for predicting whether peptides or polypeptides such as tumor-associated antigens or epitopes, in particular tumor-associated neoantigens or neoepitopes, are immunogenic and, in particular, useful for immunotherapy such as for vaccination. The methods of the invention may be used, in particular, for the provision of vaccines which are specific for a patient's tumor and, thus, in the context of personalized cancer vaccines.

Methods for predicting the usefulness of proteins or protein fragments for immunotherapy

The present invention relates to methods for predicting T cell epitopes. In particular, the present invention relates to methods for predicting whether modifications in peptides or polypeptides such as tumor-associated neoantigens are immunogenic or not. The methods of the invention are useful, in particular, for the provision of vaccines which are specific for a patient's tumor and, thus, in the context of personalized cancer vaccines.

Predicting immunogenicity of T cell epitopes

The present invention relates to methods for predicting T cell epitopes useful for vaccination. In particular, the present invention relates to methods for predicting whether modifications in peptides or polypeptides such as tumor-associated neoantigens are immunogenic and, in particular, useful for vaccination, or for predicting which of such modifications are most immunogenic and, in particular, most useful for vaccination. The methods of the invention may be used, in particular, for the provision of vaccines which are specific for a patient's tumor and thus, in the context of personalized cancer vaccines.

Predicting T cell epitopes useful for vaccination

Growing community of inventors

Obermoschel, Germany

Sebastian Boegel